All In Biotech

Drug Trial Radar · NCT00128102

Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy

Last checked: Nov 20, 2026Latest source record: Oct 26, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 661 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

661

Actual

Start

Jun 30, 2005

Primary completion

Jul 15, 2011

Study completion Nov 21, 2011

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Aug 9, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to assess the efficacy and safety of an oral investigational drug suberoylanilide hydroxamic acid (vorinostat, MK-0683) compared to placebo, in the treatment of participants with advanced malignant pleural mesothelioma who have failed at least one prior chemotherapy regimen. The primary hypotheses are the following: (1) vorinostat improves overall survival (OS) compared to placebo (2) vorinostat is generally safe and well tolerated.

Conditions

  • Mesothelioma
  • Lung Cancer

Interventions

  • VorinostatDrug

    Vorinostat 100 mg oral capsules

  • PlaceboDrug

    Vorinostat-matching placebo oral capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)
  2. Number of Participants Who Experienced Adverse Events (AEs) Characterized as Grade 3 or Grade 4 According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)Time frame: Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)
  3. Number of Participants Who Experienced an AETime frame: Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)
  4. Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.